NSCLC (EGFR-mutant / lung IO)
EGFR TKIs, PD-1/VEGF bispecifics, and RAS(ON) inhibitors competing in lung cancer.
Lenses
EarlierApproval →
AZNApprovedcash ok
2026-10-12 (-5d)Company-guided
Tagrisso EGFR franchise · NCT02151981 · Lung franchise / combo update
MRKApprovedcash ok
2026-09-25 (-22d)Company-guided
Keytruda lung IO · NCT02775435 · Lung IO label / combo update
SMMTFiledcash ok
2026-11-14 (28d)Confirmed
Ivonescimab PD-1/VEGF · NCT05184712 · PDUFA — ivonescimab
BGNEPh3cash ok
2027-01-30 (105d)Estimated
IO combo lung · NCT04746924 · Lung IO readout
MRUSPh2cash ok
2026-10-05 (-12d)Company-guided
Petosemtamab · NCT03526835 · Expansion cohort data
RVMDPh1cash ok
2027-04-01 (166d)Estimated
RAS(ON) inhibitor lung · NCT05786924 · Dose / combo update